Copyright
©The Author(s) 2023.
World J Meta-Anal. Sep 18, 2023; 11(6): 253-265
Published online Sep 18, 2023. doi: 10.13105/wjma.v11.i6.253
Published online Sep 18, 2023. doi: 10.13105/wjma.v11.i6.253
Inductors | Proliferation | Migration | Differentiation |
Heparin-binding peptide growth factors | |||
VEGF | Yes | Yes | Yes |
PlGF | Weak | Yes | Unknown |
FGF-1, FGF-2 | Yes | Yes | Yes |
PTN | Yes | Unknown | Yes |
HIV-tat protein | Weak | Weak | Yes |
PDGF | Yes | Yes | Yes |
HGF/SF | Yes | Yes | Yes |
Peptide growth factors that do not bind heparin | |||
TGF-α | Yes | Yes | Yes |
TGF-β | Inhibition | No | Yes |
EGF | Yes | Yes | Yes |
IGF-I | Yes | Yes | Yes |
Inflammatory mediators | |||
TNF-α | Inhibition | No | Yes |
IL-8 | Yes | Yes | Unknown |
IL-3 | Yes | Yes | Yes |
Prostaglandins E1, E2 | No | No | Yes |
Enzymes | |||
PD-ECGF/TP | No | Yes | Unknown |
COX-2 | No | Yes | Yes |
Angiogenin | No | Yes | Yes |
Hormones | |||
Estrogen | Yes | Yes | Yes |
Proliferin | Unknown | Yes | Unknown |
Oligosaccharides | |||
Hyaluronan oligosaccharides | Yes | Yes | Yes |
Gangliosides | Unknown | Unknown | Unknown |
Hematopoietic factors | |||
Erythropoietin | Yes | Unknown | Yes |
G-CSF | Yes | Yes | Unknown |
GM-CSF | Yes | Yes | Unknown |
Cell adhesion molecules | |||
VCAM-1 | No | Yes | Unknown |
E-selectins | No | Yes | Yes |
Integrins | No | Yes | Yes |
Semaphorins (Sema3 e 4D) | No | Yes | Yes |
Other | |||
Nitric oxide | Yes | Unknow | Unknow |
Angiopoietin-1 | No | Yes | Yes |
Molecular target of ROS | Protein or gene | Function and mechanism | Tumor type |
ERK1/ERK2 | Protein | Promotion of cell proliferation and angiogenesis | Ovarian, colon, breast, and lung cancer |
Nrf2 | Protein | Regulation of oxidative stress by modulating the production of antioxidant enzymes | NSCLC and esophageal cancer |
Ref1 /APE1 | Protein | Reduction of ROS generation | Breast cancer |
PTEN | Protein | Involvement in senescence; Association with high levels of Akt and ROS | Lung, liver, and breast cancer |
Ras | Protein | Increases mitochondrial mass and ROS levels, causing DNA damage; Regulation of Nox4-p22phox system | 30% of human cancer |
mTOR | Protein | Promotion of cell proliferation and metabolism that contributes to tumor initiation and progression; Regulation of autophagy and apoptosis | More than 70% of cancers (breast, lung, colorectal, prostate, head and neck, gynecologic, urinary bladder, renal cancer gastric carcinoma, glioblastoma, lymphoma, and medulloblastoma) |
P38 | Protein | Regulation of cell proliferation, cell differentiation, cell death, cell migration, and invasion. | Prostate, breast, bladder, live, and lung cancer, transformed follicular lymphoma and leukemia |
BRCA | Gene | Regulation of antioxidant response; Controlling the Nrf2 and NFκB activity | 40%-50% of hereditary breast cancers |
hTERT | Protein | Reduces oxidative stress intracellularly and extracellularly; Regulation of apoptosis | Gastric cancer, lung cancer, cervical and head cancer, glioblastoma, breast cancer, and ovarian cancer |
Angiopoietin | Protein | Involvement in angiogenesis, lymphangiogenesis, and metastasis; Induction of hypoxia and cytokines | NSCLC |
- Citation: Andriolo LG, Cammisotto V, Spagnoli A, Alunni Fegatelli D, Chicone M, Di Rienzo G, Dell’Anna V, Lobreglio G, Serio G, Pignatelli P. Overview of angiogenesis and oxidative stress in cancer. World J Meta-Anal 2023; 11(6): 253-265
- URL: https://www.wjgnet.com/2308-3840/full/v11/i6/253.htm
- DOI: https://dx.doi.org/10.13105/wjma.v11.i6.253